Novartis Eyes Rare Kidney Disease Approvals on Heels of Two Phase III Wins

Novartis on Saturday posted two promising Phase III readouts in rare kidney diseases, setting the pharma up for two potential approvals in the space. The company presented these data at the European Renal Association Congress over the weekend.